The impact of cefepime as first line therapy for neutropenic fever on Clostridium difficile rates among hematology and oncology patients

被引：11

作者：

Muldoon, Eavan G. ^{[1
]}

Epstein, Lauren ^{[1
]}

Logvinenko, Tanya ^{[2
]}

Murray, Susan ^{[1
]}

Doron, Shira I. ^{[1
]}

Snydman, David R. ^{[1
]}

机构：

[1] Tufts Med Ctr, Div Geog Med & Infect Dis, Boston, MA USA

[2] Tufts Med Ctr, Biostat Res Ctr, Boston, MA USA

来源：

ANAEROBE | 2013年 / 24卷

基金：

美国国家卫生研究院;

关键词：

Clostridium difficile; Cefepime; Neutropenic sepsis; Antimicrobial stewardship; OUTBREAK; DISEASE;

D O I：

10.1016/j.anaerobe.2013.10.001

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

After changing empiric treatment of febrile neutropenia from meropenem to cefepime, the effect on Clostridium difficile infection (CDI) was investigated. The change was assessed using an autoregressive model. A significant increase in CDI rates occurred following the introduction of cefepime. There may be an association between increased cefepime usage and CDI. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：79 / 81

页数：3

共 10 条

[1]

Aldeyab M. A., J. Antimicrob. Chemother

[2]

Barkin JA, 2011, 111 GEN M AM SOC MIC

[3] A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with Hematologic malignancies [J].

Bow, E. J. ;

Rotstein, C. ;

Noskin, G. A. ;

Laverdiere, M. ;

Schwarer, A. P. ;

Segal, B. H. ;

Seymour, J. F. ;

Szer, J. ;

Sanche, S. .

CLINICAL INFECTIOUS DISEASES, 2006, 43 (04) :447-459

[4] Successful combat of an outbreak due to Clostridium difficile PCR ribotype 027 and recognition of specific risk factors [J].

Debast, S. B. ;

Vaessen, N. ;

Choudry, A. ;

Wiegers-Ligtvoet, E. A. J. ;

van den Berg, R. J. ;

Kuijper, E. J. .

CLINICAL MICROBIOLOGY AND INFECTION, 2009, 15 (05) :427-434

[5] Clostridium difficile-associated disease in a setting of endemicity:: Identification of novel risk factors [J].

Dubberke, Erik R. ;

Reske, Kimberly A. ;

Yan, Yan ;

Olsen, Margaret A. ;

McDonald, L. Clifford ;

Fraser, Victoria J. .

CLINICAL INFECTIOUS DISEASES, 2007, 45 (12) :1543-1549

[6] Executive Summary: Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America [J].

Freifeld, Alison G. ;

Bow, Eric J. ;

Sepkowitz, Kent A. ;

Boeckh, Michael J. ;

Ito, James I. ;

Mullen, Craig A. ;

Raad, Issam I. ;

Rolston, Kenneth V. ;

Young, Jo-Anne H. ;

Wingard, John R. .

CLINICAL INFECTIOUS DISEASES, 2011, 52 (04) :427-431

[7] A large outbreak of Clostridium Difficile -: Associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use [J].

Muto, CA ;

Pokrywka, M ;

Shutt, K ;

Mendelsohn, AB ;

Nouri, K ;

Posey, K ;

Roberts, T ;

Croyle, K ;

Krystofiak, S ;

Patel-Brown, S ;

Pasculle, AW ;

Paterson, DL ;

Saul, M .

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2005, 26 (03) :273-280

[8] Antimicrobial-associated risk factors for Clostridium difficile infection [J].

Owens, Robert C., Jr. ;

Donskey, Curtis J. ;

Gaynes, Robert P. ;

Loo, Vivian G. ;

Muto, Carlene A. .

CLINICAL INFECTIOUS DISEASES, 2008, 46 :S19-S31

[9] ANTIBACTERIAL ACTIVITY OF MEROPENEM AND SELECTED COMPARATIVE AGENTS AGAINST ANAEROBIC-BACTERIA AT 7 NORTH-AMERICAN CENTERS [J].

SHEIKH, W ;

PITKIN, DH ;

NADLER, H .

CLINICAL INFECTIOUS DISEASES, 1993, 16 :S361-S366

[10] Impact of guidelines and enhanced antibiotic stewardship on reducing broad-spectrum antibiotic usage and its effect on incidence of Clostridium difficile infection [J].

Talpaert, Moira Joelle ;

Rao, Guduru Gopal ;

Cooper, Ben Symons ;

Wade, Paul .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (09) :2168-2174

← 1 →